Acute Respiratory Distress Syndrome after Topotecan Therapy in a Patient with Small Cell Lung Cancer / 결핵및호흡기질환
Tuberculosis and Respiratory Diseases
;
: 142-146, 2008.
Article
in Korean
| WPRIM
| ID: wpr-182743
ABSTRACT
Small cell lung cancer is characterized by an aggressive clinical course and a high tendency for early dissemination in spite of a good chemotherapy response. Topotecan is a topoisomerase I inhibitor, and it is used as second-line treatment for small cell lung cancer. The reported dose-limiting adverse reactions to topotecan are mainly hematologic. Yet pulmonary toxicity associated with topotecan is known to be rare. We report here on a case that showed the development of acute respiratory distress syndrome during the 3rd cycle of topotecan chemotherapy in a patient with small cell lung cancer. He developed dyspnea and respiratory failure, and the chest CT scan revealed diffuse ground-glass opacity that was probably due to chemotherapy-related pulmonary toxicity. He finally died of acute respiratory distress syndrome.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Respiratory Distress Syndrome
/
Respiratory Insufficiency
/
Thorax
/
Carcinoma, Small Cell
/
DNA Topoisomerases, Type I
/
Topotecan
/
Dyspnea
/
Small Cell Lung Carcinoma
Limits:
Humans
Language:
Korean
Journal:
Tuberculosis and Respiratory Diseases
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS